In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more.

• Intro :58
• The interview/about Regueiro 1:03
• Tell us about your family and where you grew up. 1:24
• How did you get interested in medicine? 2:16
• Who were your early influences? 4:18
• What is the medical home? 5:57
• How did you develop the idea to apply the medical home model to IBD? 7:45
• Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57
• Why hasn’t this model become standard of care for patients with complex IBD? 14:13
• What has worked, and what hasn’t worked when it comes to adopting an integrative care medical home model? 18:15
• Are there themes patients share as to why they wouldn’t want to be enrolled in a medical home? 21:28
• What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09
• What have you learned in this position at Cleveland Clinic? 25:23
• Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34
• How would you recommend that people prepare for having a position like this? 27:34
• Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02
• With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06
• What are the challenges that you still see in the ways we are using telehealth? 39:05
• What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26
• Thank you, Miguel 42:55
• Thanks for listening 45:11

Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X.

Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more.

• Intro :24
• The interview/about Stidham :36
• Tell us about your family and where you grew up. 1:14
• How did you embrace changes in technology growing up? 3:07
• What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator? 6:05
• What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32
• Can you give a quick overview of what these tools and technologies entail? 12:52
• What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12
• Where did your interest in AI come about? 20:26
• You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58
• How do we change the way we train GI doctors, and should we start making these changes today? 26:38
• With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33
• What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06
• What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39
• Thank you, Ryan 44:04
• Thanks for listening 44:20

Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X.

Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

In this special crossover episode with Physicianary, previous Gut Talk guest, Austin Chiang, MD, and Physicianary host, Hansa Bhargava, MD, discuss the influence of social media in medicine and how AI continues to change the health care landscape.

• Intro 0:30
• Austin Chiang, MD, MPH 0:36
• Tell us about your journey. 1:02
• How did you get involved with being a social media officer at your institution? 3:58
• Where do you think doctors should see themselves in the future of social media in medicine? 6:49
• What are the ways in which you see AI tech making a difference? 9:12
• Do you agree that it is helpful for doctors to be involved with product development and integration on an industry level? 12:14
• Can you give us some insight on the process of putting through new CPT codes as a company? 14:41
• Tell me more about your book, Gut: An Owner's Guide (The Body Literacy Library). What motivated you to write this book, and what do you think people will get out of it? 18:35
• If you were the “king of health care”, what would you work on first? What is the most important aspect of health car that you think needs fixing? 21:23
• What’s your favorite food? 25:24
• How to reach Chiang. 26:01
• Thanks 26:20

Austin Chiang, MD, MPH, is the first chief medical officer for the endoscopy business of Medtronic, the global leader in health technology. He is also currently an assistant professor of medicine at an academic teaching hospital in Philadelphia, PA, and serves as the director of the Endoscopic Weight Loss Program.

Listen to Gut Talk’s very first episode with Dr. Chiang from 2019, Social Media in Medicine.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Follow Dr. Bhargava on X @hansabhargavaMD and on Instagram @doctorhansaMD. Follow Dr. Chiang everywhere on social media @AustinChiangMD.

Disclosures: Bhargava reports no relevant financial disclosures. Chiang reports he is the chief medical officer for Medtronic Endoscopy.